GSK and Adolor Corp. have reported mixed results from two Phase 3 trials of alvimopan in opioid-induced bowel dysfunction in patients with chronic non-cancer pain, saying one study achieved statistical significance while the other didn't.
As usual they are planning some dredging of secondary endpoints to try and find some good news.
But it doesn't sound hopeful.
Dow Jones
No comments:
Post a Comment